COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL

Raja Atreya  ¹     Laurent Peyrin–Biroulet  ²     Andrii Klymenko  ³     Monica Augustyn  ⁴     Igor Bakulin  ⁵     Dusan Slankamenac  ⁶     Pal Miheller  ⁷     Antonio Gasbarrini  ⁸     Xavier Hebuterne  ⁹     Karin Arnesson  ¹⁰     Thomas Knittel  ¹⁰     Jan Kowalski  ¹⁰     Markus F. Neurath  ¹¹     William Sandborn  ¹²     Walter Reinisch  ^13    
1 University Erlangen-Nürnberg, Erlangen, Germany
² Nancy University Hospital, Nancy, France
³ Zaporozhye State Medical University, Zaporozhye, Ukraine
⁴ Centrum Medyczne Plejady, Krakow, Poland
⁵ Mechnikov North-Western State Medical University, Saint-Petersburg, Russian Federation
⁶ General Hospital Zrenjanin, Zrenjanin, Serbia
⁷ Semmelweis Egyetem, Budapest, Hungary
⁸ Universitario Agostino Gemelli, Rome, Italy
⁹ CHU de Nice and University Côte d’Azur, Nice, France
¹⁰ InDex Pharmaceuticals, Stockholm, Sweden
¹¹ University of Erlangen-Nürnberg, Erlangen, Germany
¹² University of California San Diego, La Jolla, United States
¹³ Medical University of Vienna, Vienna, Austria

Topic
IBD

Session
IBD: Clinical trials III

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)